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Despite the potential cancer preventive effects of flavonoids and lignans, their ability to reduce pancreatic cancer risk has not
been demonstrated in epidemiological studies. Our aim was to examine the association between dietary intakes of flavonoids
and lignans and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A
total of 865 exocrine pancreatic cancer cases occurred after 11.3 years of follow-up of 477,309 cohort members. Dietary flavo-
noid and lignan intake was estimated through validated dietary questionnaires and the US Department of Agriculture (USDA)
and Phenol Explorer databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated using age, sex and
center-stratified Cox proportional hazards models, adjusted for energy intake, body mass index (BMI), smoking, alcohol and
diabetes status. Our results showed that neither overall dietary intake of flavonoids nor of lignans were associated with pan-
creatic cancer risk (multivariable-adjusted HR for a doubling of intake51.03, 95% CI: 0.95–1.11 and 1.02; 95% CI: 0.89–
1.17, respectively). Statistically significant associations were also not observed by flavonoid subclasses. An inverse associa-
tion between intake of flavanones and pancreatic cancer risk was apparent, without reaching statistical significance, in micro-
scopically confirmed cases (HR for a doubling of intake50.96, 95% CI: 0.91–1.00). In conclusion, we did not observe an
association between intake of flavonoids, flavonoid subclasses or lignans and pancreatic cancer risk in the EPIC cohort.
Pancreatic cancer incidence and mortality estimates for the
year 2012 in Europe show that the prognosis of this cancer
remains poor (mortality:incidence ratio is 0.98).1 Age, sex,
family history, smoking, chronic pancreatitis, obesity and dia-
betes are established risk factors,2 but no dietary factors have
been classiﬁed as convincingly associated with pancreatic can-
cer risk.3 Identiﬁcation of dietary factors, including bioactive
compounds naturally present in food, are increasingly the
focus of investigation to reduce the burden of this cancer.4
Flavonoids and its subclasses (ﬂavones, ﬂavonols, ﬂava-
nones, ﬂavanols—including ﬂavan-3-ol monomers, proantho-
cyanidins, and theaﬂavins—anthocyanidins, and isoﬂavones)
are bioactive compounds with phenolic structures commonly
present in fruits, vegetables and plant-based beverages.5 These
antioxidant compounds exert putative anticarcinogenic effects
through a wide range of molecular mechanisms.6 Epidemio-
logical evidence of their role in cancer prevention is, how-
ever, still inconsistent. For instance, some studies point to a
reduced risk of various smoking-related cancers,7,8 while
others have not demonstrated an inverse association with
cancer risk.9,10 Lignans are another diverse group of polyphe-
nols present in foods of plant origin and one of the major
classes of phytoestrogens. They also seem to have anticancer
activity, possibly via pro-estrogenic mechanisms or antioxi-
dant effects,5 although fewer studies have examined their
cancer preventive effects.11
The anticancer effects of ﬂavonoids on pancreatic cancer
have been widely researched in in vitro and in vivo studies.
What’s new?
Flavonoids and lignans found in plant-based foods are potent cancer chemopreventive agents but little is known about their
effects on pancreatic cancer risk. Here the authors address this question in a large prospective epidemiological study using
comprehensively derived dietary data. Their results support growing evidence that there is no association between food-based
consumption of both substances with pancreatic cancer risk.
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These studies suggest that ﬂavonoids inhibit proliferation of
various pancreatic cancer cell lines through induction of
apoptosis and inhibition of cell growth.4 Epidemiological
studies examining the association between ﬂavonoids on pan-
creatic cancer risk include seven prospective studies,9,12–17
and one case-control study.18 A ﬂavonoid-rich food pattern
and the intake of ﬂavonols were both associated with a
reduced pancreatic cancer risk in the Multiethnic cohort
study (MEC), with this association being more prominent in
smokers.17,19 This ﬁnding was, however, not conﬁrmed in a
Finnish cohort study, except when smokers not consuming
antioxidant supplements were considered.14 The case-control
study conducted in Italy reported an inverse association with
pancreatic cancer risk for proanthocyanidin intake.18 In con-
trast, ﬁndings of a large prospective study that included 2,379
pancreatic cancer cases (within the National Institutes of
Health-AARP Diet and Health Study, NIH-AARP) did not
support an association between ﬂavonoid intake and pancre-
atic cancer risk.13 The other studies, which had smaller sam-
ple sizes, also did not observe signiﬁcant associations for the
intake of total ﬂavonoids or subclasses with pancreatic cancer
risk. The association between dietary intake of lignans and
pancreatic cancer risk has not yet been examined in
epidemiological studies.
A compelling argument of a possible lack of association
between dietary ﬂavonoids and lignans with pancreatic cancer
risk is that fruits, their major food sources, seem not to play
a role in the aetiology of this cancer.20 However, an associa-
tion between intake of ﬂavonoids and lignans with pancreatic
cancer risk is plausible given their observed preventative
effects against diabetes.21,22
Our aim was to examine the association between dietary
intakes of ﬂavonoids and lignans and pancreatic cancer risk
in the European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort, in which a diverse intake of these
compounds was described.23,24
Methods
Study design
The EPIC study is a multicenter prospective cohort study
that is being carried out in 23 centers from 10 European
countries (Denmark, France, Germany, Greece, Italy, Norway,
Spain, Sweden, The Netherlands and United Kingdom).
Recruitment of over half a million participants, aged 25–70
years, took place between 1992 and 2000. The majority of the
participants were recruited from the general population
although some centers also constituted their cohorts with
local blood donors (Spain and Italy), vegetarians (the health
conscious cohort of Oxford in the UK), women attending
breast cancer screening programs (Florence in Italy and
Utrecht in The Netherlands), or women belonging to a health
insurance scheme for state school and university employees
(France). Participants gave their informed consent for partici-
pating in the study. The study was approved by the Internal
Review Board of the International Agency for Research on
Cancer, as well as by local institutions of the participating
centers. Methods of recruitment have been described in detail
elsewhere.25,26
Study population
A total of 23,785 participants with prevalent cancer at base-
line other than non-melanoma skin cancer, 4,383 participants
with missing or incomplete information on follow-up, 6,253
participants with incomplete dietary or non-dietary informa-
tion, and 9,600 participants with a ratio for energy intake
versus energy expenditure in the top or bottom 1% were
excluded. The ﬁnal study sample consisted of 477,309 partici-
pants (29.8% men).
Assessment of the outcome
Record linkage with population-based cancer registries, as
well as with national mortality registries, was performed to
identify incident cancer cases and to assess the vital status of
the participants. Complete follow-up data was obtained until
at least December 2004 and maximally to December 2008
depending on the EPIC center. Active follow-up was carried
out in Germany (up to December 2008 for Potsdam and
June 2010 for Heidelberg), Greece (up to December 2009),
and France (up to December 2006) by reviewing cancer,
pathology and health insurance records of each participant,
and also by directly contacting their next-of-kin.
Incident pancreatic cancer cases were deﬁned as adenocar-
cinomas of the exocrine pancreas [International Classiﬁcation
of Diseases for Oncology, Third Edition (ICD-O-3), codes
C25.0–C25.3, C25.7–C25.9]. Endocrine tumors (n5 40), sec-
ondary tumors (n5 67) and tumors of uncertain, benign or
metastatic behavior (n5 3) were all censored at the date of
their diagnosis. Of all 865 exocrine pancreatic cancer cases,
608 (70.3%) were microscopically conﬁrmed, based on histol-
ogy of the primary tumor (n5 359), histology of the metasta-
sis (n5 68), cytology (n5 130) or autopsy (n5 51).
Diagnosis was based on clinical symptoms, physical examina-
tion or imaging results for the remaining cases.
Assessment of diet and lifestyle data
Country-speciﬁc validated dietary questionnaires (DQs) were
used to inquire the participants about their habitual diet over
the previous year, namely: quantitative food frequency ques-
tionnaires (FFQs) in Germany, Greece, UK, Northern Italy
and The Netherlands, diet history questionnaires in Spain,
France and Ragusa (Italy), and semi-quantitative FFQs in
Denmark, Naples (Italy), Norway, Umea (Sweden). In Malm€o
(Sweden), quantitative questionnaire with a 7-day menu book
were used.26 The EPIC nutrient database (ENDB) was used
to estimate nutrient and total energy intake.27 Intake of total
ﬂavonoids and its subclasses (ﬂavones, ﬂavonols, ﬂavanones,
ﬂavanols—including ﬂavan-3-ol monomers, proanthocyani-
dins, and theaﬂavins—anthocyanidins, and isoﬂavones) as
well as intake of lignans was estimated through databases on
content of polyphenols in foods.28–30 Effects of food
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processing and cooking on polyphenol content were consid-
ered by reported values in the above mentioned databases, or
by applying retention factors.31 Information on dietary ﬂavo-
noids and lignans was available for 1,877 food items. More
details on the estimation of the dietary intake of ﬂavonoids
and lignans have been described elsewhere.23,24
Other lifestyle data were collected at recruitment using
standardized questionnaires including self-reported diabetes
mellitus status, lifetime history of smoking and alcohol con-
sumption, physical activity and socio-economic status.
Approximately half of all diabetes self-reported cases were
included in a validation study, which consisted of verifying
this diagnosis using additional sources of information, such
as use of diabetes-related medication, repeated self-report
during follow-up, or linkage to diabetes registries and patient
records.32 Regarding anthropometrics, participant’s height
and weight were measured in all EPIC centers except in Nor-
way, France and in a subgroup of the Oxford cohort where
these data were self-reported. Measurements also included
waist circumference except in Norway and Umea and in the
Oxford cohort where these data were self-reported.26 This
data was corrected for differences in clothing and also for
self-reports through prediction equations based on real meas-
ures in a subsample of the French and Oxford cohorts.33
Statistical analysis
Cox proportional hazards regression models were used to
estimate hazard ratios (HRs) and 95% conﬁdence intervals
(CIs) for intake of total ﬂavonoids, ﬂavonoid subclasses and
lignans associated with pancreatic cancer risk. Regression
models were stratiﬁed by age at recruitment in 1-year catego-
ries, sex and center to additionally control for between-center
differences in the dietary assessment methods used at recruit-
ment and differences in follow-up procedures. Time at entry
was age at recruitment, and time at exit was age at ﬁrst pan-
creatic cancer diagnosis for cases and age at censoring for
non-cases (death, loss to follow-up, or end of the follow-up,
whichever came ﬁrst). The proportional hazard assumption
was satisﬁed as was veriﬁed after including time dependent
covariates in the Cox models and testing for a non-zero slope
in a linear regression of the scaled Schoenfeld residuals on
functions of time.34 Intake of dietary ﬂavonoids and lignans
were modelled as categorical variables using cohort-wide
quintiles and considering the ﬁrst quintile as the referent.
The trend of association across quintiles was evaluated by
using a linear variable of the quintile-speciﬁc medians of the
dietary intakes.
Intakes were also modelled on a continuous log2 scale to
estimate risks associated with a doubling of intake and to
normalize the skewed data. We previously examined the
shape of the dose–response relationship by ﬁtting Cox mod-
els with restricted cubic splines using three knots on the 5th,
50th, and 95th percentile of the distribution of ﬂavonoids
and lignan intakes.35 These models suggested a linear rela-
tionship for total ﬂavonoids, ﬂavonoid subclasses, and for
lignans. Linearity was maintained with a larger number of
knots.
Covariates considered a priori as factors associated with
pancreatic cancer risk and dietary intake of ﬂavonoids and
lignans were tested for confounding by comparing models
with and without each variable. Those variables that changed
estimates >10% or signiﬁcantly improved the model ﬁt likeli-
hood ratio test were retained in the regression model. Physi-
cal activity, educational level, waist circumference and dietary
factors possibly associated with pancreatic cancer risk (folate,
ﬁber, saturated fatty acids, red and processed meat) did not
comply with these criteria and were therefore not retained.
The associations of dietary ﬂavonoids and lignans intakes
with pancreatic cancer risk were examined in crude models
(stratiﬁed by age, sex, and center), which were further
adjusted (Model 1) for energy intake from fat and from non-
fat sources, and additionally (Model 2) for body mass index
(BMI), smoking status, alcohol intake, and diabetes status at
recruitment.
We conducted stratiﬁed analyses and tested interaction
using the log-likelihood test in regression models with and
without multiplicative interaction terms to examine the mod-
ifying effect of sex, BMI (normal vs. overweight and/or obese,
considering WHO criteria36), waist circumference (normal vs.
moderate and large, considering NCEP/ATPIII criteria37),
smoking status (never vs. former vs. current smoker), median
age at diagnosis (<60 vs. 60 years), and heterogeneity by
country and region (mediterranean vs. non-mediterranean).
The potential interaction between intake of ﬂavonoids and
lignans and smoking status was further explored on an addi-
tive scale, using a ﬁve-category variable for ﬂavonoids (quin-
tiles) and a three-category variable for smoking status (never,
former and current smokers).
Sensitivity analyses were conducted by excluding the ﬁrst
2 years of follow-up (excluding 88 cases) to evaluate whether
reverse causation driven by early effects of subclinical disease
distorted the associations, and excluding the microscopically
non-conﬁrmed cases (n5 257) to minimize possible misclas-
siﬁcation of tumors. We also stratiﬁed the associations by
diabetes status to explore whether diabetes mediates and/or
moderates the possible association between dietary intake of
ﬂavonoids and lignans with risk of pancreatic cancer. How-
ever, the associations could only be examined in non-
diabetics, including 773 pancreatic cancer cases, due to insuf-
ﬁcient number of pancreatic cancer cases with diabetes at
recruitment (55 cases).
Stata statistical software was used for the data analysis
(release 12.0; College Station, TX: Stata Corp LP, 2005). Sta-
tistical signiﬁcance was based on two-sided p values< 0.05.
Results
In total, 865 pancreatic cancer cases (45.8% in men) were
documented after 11.3 years of follow-up. Median intake of
ﬂavonoids in men and women was 335.0 and 332.2
mg day21, respectively. Intakes were highest in the UK,
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possibly due to the high proportion of health conscious par-
ticipants and tea drinkers in this cohort, and lowest in Nor-
wegian women and Swedish men and women. For lignans
(median intakes: 1.46 mg day21 in men and 1.23 mg day21
in women), a similar pattern was observed. The main con-
tributors to the intake of total ﬂavonoids were ﬂavanols
(82.1%) followed by ﬂavonols (6.1%) in men, and ﬂavanols
(80.8%) followed by anthocyanidins (6.8%) in women. The
composition of ﬂavonoids subclasses in the diet differed by
country, with ﬂavanols being overall the most frequently con-
sumed ﬂavonoid subclass (Table 1).
The characteristics of the study population are described
in Table 2. Brieﬂy, participants in the ﬁfth quintile of dietary
intake of ﬂavonoids and lignans were older, had a lower BMI
and waist circumference, and were less likely to be smokers
and diabetics compared to participants in the ﬁrst quintile.
Participants with higher dietary intakes of ﬂavonoids and
lignans also consumed higher amounts of alcohol, achieved a
higher educational level and were more physically active. All
dietary factors increased across quintiles of intake of total ﬂa-
vonoids and lignans, except intake of red and processed
meat.
Neither dietary intake of total ﬂavonoids nor of lignans
were associated with risk of pancreatic cancer (HR for a dou-
bling of intake after a log2 transformation5 1.03, 95%
CI: 0.95–1.11 and 1.02; 95% CI: 0.89–1.17, respectively)
(Table 3). None of the subclasses of ﬂavonoids showed a stat-
istically signiﬁcant association with pancreatic cancer risk,
although results of ﬂavonols, ﬂavan-3-ol monomers and thea-
ﬂavins suggested a positive association across quantiles
(p trend5 0.06, 0.05, and 0.04, respectively). Risk of pancre-
atic cancer risk tended to decrease with higher intake of ﬂa-
vanones (HR Q5 vs. Q15 0.78, 95% CI: 0.61–0.99,
p trend5 0.07), but not so after multivariable adjustment
(p trend5 0.24). The associations were all not statistically sig-
niﬁcant on the continuous scale. Adjustment for smoking sta-
tus affected the associations most, while adjustment by the
other variables had barely an effect.
No statistically signiﬁcant heterogeneity between countries
was observed for the associations of total ﬂavonoids
(p5 0.21) and lignans (p5 0.81) with pancreatic cancer risk;
the same applied for the analyses by regions. Interactions for
total ﬂavonoids and lignan intake were also not observed for
sex (p5 0.64 and p5 0.39), BMI (p5 0.67 and p5 0.26),
smoking status (p5 0.14 and p5 0.15), waist circumference
(p5 0.83 and p5 0.66) and age (p5 0.47 and p5 0.89).
There was also no evidence for interaction by these variables
for any of the ﬂavonoids subclasses (data not shown). An
inverse association between intake of ﬂavanone and pancre-
atic cancer risk was apparent, though not statistically signiﬁ-
cant, in smokers (HR log25 0.96, 95% CI: 0.89–1.02).
Additionally controlling for smoking duration or intensity
did not affect the risk estimates (Supporting Information
Table 1). The combined effect of ﬂavonoids and lignans with
smoking on the risk of pancreatic cancer did not appreciablyTa
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alter the associations with increasing intakes among never or
former smokers with respect to smokers with the lowest cate-
gory of intake (data not shown).
In the sensitivity analyses (Table 4), the associations
between dietary intake of total ﬂavonoids and lignans with
pancreatic cancer risk remained almost unchanged. By ﬂavo-
noids subclasses (Supporting Information Table 2), some
associations changed to some extent after restricting the anal-
yses to microscopically conﬁrmed pancreatic cancer cases; for
instance, in multivariable adjusted models, participants in the
highest quintile of ﬂavanone intake (compared to the lowest
quintile) had a 29% lower pancreatic cancer risk (95% CI:
0.53–0.95, p trend5 0.045), although statistical signiﬁcance
was not reached on the continuous scale (HR log2: 0.96, 95%
CI: 0.91–1.00). On the other hand, the positive trends
observed for ﬂavonols, ﬂavan-3-ol monomers and theaﬂavins
were all attenuated (p trend5 0.17, 0.18 and 0.2, respec-
tively). The associations in nondiabetics weakened overall.
Exclusion of cases diagnosed in the ﬁrst 2 years of follow-up
had a minor impact on risk estimates.
Discussion
The results of the present study do not support an associa-
tion between dietary intakes of total ﬂavonoids, ﬂavonoids
subclasses or lignans with risk of pancreatic cancer. Intake of
ﬂavanones tended to be inversely associated with pancreatic
cancer risk only when microscopically conﬁrmed cases were
considered, but the results were not statistically signiﬁcant.
No other variables exerted a differential effect on these
associations.
The beneﬁcial effect of fruits and vegetables against cancer
has been attributed to ﬁber, vitamins and to ﬂavonoids
because of their well-established antioxidant, antimutagenic,
and antiproliferative properties.6 With regard to pancreatic
cancer, in vitro and in vivo animal studies have implicated
the anticarcinogenic activity of ﬂavonoids via various biologi-
cal mechanisms inﬂuencing cell signalling, cell-cycle regula-
tion and angiogenesis, such as down regulation of NF-kB
activity with suppression of Akt activation, induction of apo-
ptosis on BxPC-3 in MIA PaCa-2 and PANC-1 cells, or inhi-
bition of glucose uptake through down regulation of GLUT-1
in CD18 cells.4,6 The possible chemopreventive effects of ﬂa-
vonoids are, however, less evident in epidemiological studies
(Supporting Information Table 3): Intake of ﬂavonols was
reported to be inversely associated with pancreatic cancer
risk in the MEC study (HR comparing extreme quintiles:
0.77, 95% CI: 0.58–1.03), which included 529 pancreatic can-
cer cases.17 This trend of decreasing risk was manifest in all
subclasses (quercetin, myricetin and kaempferol), with
kaempferol showing the largest risk reduction (p
trend5 0.02), and with a stronger association observed in
smokers (HR5 0.41, 95% CI: 0.22–0.74). A dietary pattern
regarded as rich in ﬂavonols was also found to decrease pan-
creatic cancer risk in smokers participating in the MEC
study, but this was not conﬁrmed in a validation study con-
ducted within the EPIC cohort.19 Increasing intake of ﬂavo-
noids also decreased pancreatic cancer risk in male smokers
not consuming supplemental vitamins in the alpha-
tocopherol, beta-carotene cancer prevention (ATBC) study
(n5 306 cases).14 Both were the only studies supporting an
inverse association in smokers, which could be ascribed to
the known anti-oxidative effect (inhibition of CYP450
enzymes) elicited by ﬂavonoids.4 We did not observe an
inverse association in smokers, except a suggestive, but not
statistically signiﬁcant, inverse association between ﬂavanones
and pancreatic cancer risk.
Other prospective studies did not ﬁnd any association
between intake of ﬂavonoids and risk of pancreatic cancer.
For instance, the largest prospective study conducted so far,
which included 2,379 pancreatic cancer cases of the NIH-
AARP cohort, concluded that intake of ﬂavonoids was not
associated with pancreatic cancer risk (HR comparing
extreme quintiles: 1.09, 95% CI: 0.96–1.24).13 Two earlier
studies conducted within the Iowa Women’s Health Study
also reported a null association for total ﬂavonoids and seven
subclasses (n5 230 cases),15 and for catechins (n5 130
cases).12 There were also no associations with pancreatic can-
cer either for total ﬂavonoids or subclasses in the Women’s
health study (n5 not reported),9 and in a Finnish
population-based survey (n5 29 cases),16 although both stud-
ies were more prone to chance ﬁndings due their smaller
sample size. Finally, a case-control study carried out in Italy,
which included 326 pancreatic cancer cases, suggested an
inverse association with pancreatic cancer risk for proantho-
cyanidins (OR comparing extreme quintiles5 041; 95% CI:
0.24–0.69, p trend5 0.001).18
Comparison between these studies is, to some extent, lim-
ited by several issues in relation to (Supporting Information
Table 3): differences in the study populations, varying ranges
of intake and in dietary assessment methods used, e.g. data-
bases on ﬂavonoids content in food, the number of food
items used for the evaluation of intake of ﬂavonoids, and
whether the inﬂuence of food processing on ﬂavonoids con-
tent was taken into consideration.12,13,15 In addition, in some
studies, fewer ﬂavonoids subclasses were considered to esti-
mate intake of total ﬂavonoids,9,14,16 while other studies
focused on a single subclass,12,17 and only few studies consid-
ered individual subclasses of ﬂavonoids.14,15,18 Only the NIH-
AARP overcame most of these limitations by considering all
subclasses of ﬂavonoids (except proanthocyanidins), and
accounting for ﬂavonoids values of processed foods and rec-
ipes.13 Likewise, our study presents results obtained using
both a relatively large sample size and a comprehensive esti-
mation of intake of ﬂavonoids. Despite the heterogeneity
between studies, our results agree with the majority of the
studies indicating a lack of association between dietary intake
of ﬂavonoids and risk of pancreatic cancer. The fact that in
vivo and in vitro effects of ﬂavonoids disagree with data from
epidemiological studies might be due to the poor bioavailabil-
ity of these compounds, to dietary intakes at levels that are
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under the threshold of their biological activity,5 or due to
measurement errors in the dietary assessment methods. In
fact, only two studies considered proanthocyanidins for the
quantiﬁcation of ﬂavanols.15,18 More reliable estimates of
exposure through the use of biomarkers may allow a better
understanding of the role of polyphenols in the aetiology of
diseases, such as pancreatic cancer.38
A large proportion of the pancreatic cancer cases in our
cohort were microscopically conﬁrmed. An inverse associa-
tion of borderline signiﬁcance became apparent between ﬂa-
vanones and pancreatic cancer risk after restricting the
analysis to these cases. The positive trend we observed for
ﬂavan-3-ol monomers, ﬂavonols and theaﬂavins, was not
consistent in all our analyses nor statistically signiﬁcant, and
is also not supported by the fact that the major food sources
of these subclasses (tea, coffee, fruits and vegetables) are not
linked to pancreatic cancer risk.20,39,40
Stratiﬁed analyses by diabetes status revealed that ﬂavo-
noids and lignans were not inversely associated with pancre-
atic cancer in nondiabetics. In a previous study within the
EPIC-InterAct study, an inverse association between these
subclasses and risk of type 2 diabetes was observed.21
Although dietary intake of lignans was not associated with
diabetes in the EPIC-InterAct study,21 gut microbiota metab-
olites of lignans have been associated with a lower risk of
diabetes in the Nurses’ Health Study.41
Flavonoids and lignans may reduce the long-term damag-
ing effects of diabetes by improving insulin secretion, increas-
ing glucose uptake and reducing insulin resistance,42 which
could in turn reduce inﬂammation and oxidative stress
induced by hyperglycaemia, and consequently reduce pancre-
atic cancer risk.43 We could not test this hypothesis due to
limited number of participants with diabetes at recruitment
who developed pancreatic cancer thereafter (n5 55).
Several strengths of this study merit consideration. The
large sample size and long follow-up enabled stratiﬁed analy-
sis by smoking status and other potential effect modiﬁers
with sufﬁcient statistical power. Another major strength and
distinguishing feature of our study is that we were able to
minimize bias due to misclassiﬁcation of cases after restrict-
ing the study population to microscopically conﬁrmed pan-
creatic cancer cases. The inﬂuence of prediagnostic disease
on the associations is unlikely since exclusion of cases diag-
nosed within the ﬁrst 2 years of follow-up did not alter the
associations. Our study also beneﬁts from an exhaustive
quantiﬁcation of intake of ﬂavonoids, at a combined and
individual basis for seven subclasses.23 This study also
presents several limitations. Dietary measurement error may
have led to some misclassiﬁcation of the dietary exposure.
The regression calibration approach to correct measurement
error was, however, not suitable given that ﬂavonoids and
lignans are contained in speciﬁc foods only.44 It is also possi-
ble that intake of ﬂavonoids and lignans is underestimated
due to incomplete information on their content in some
foods, such as thearubigins for tea, or unknown composi-
tional data of some lignans,23 and because we could not con-
sider dietary supplements (herbs/plants or their constituents)
as another source of intake. The latter should not have
affected our results as these types of products represented 8–
17% of the supplements used in the EPIC study.45 Residual
confounding might be present as we did not control for all
potential confounding factors such as family history of pan-
creatic cancer, history of pancreatitis, and other unmeasured
variables or unknown factors. Residual confounding by
smoking could also have been present, despite the fact that
accounting for smoking duration and intensity did not sub-
stantially affect the results. Misclassiﬁed diabetes status could
have biased our results, but consideration of either self-
reported or validated data on type 2 diabetes status at base-
line made no substantial difference in the results.
In conclusion, this study does not support an association
between dietary intakes of total ﬂavonoids, ﬂavonoids sub-
classes, or lignans and pancreatic cancer risk in the EPIC
cohort.
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